Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06439914 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy
A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Nerissa T. Viola.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT06439914: Recruiting Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Nerissa T. Viola.
NCT06439914 is a Phase 1 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Nerissa T. Viola. The registered enrollment target is 6 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06439914, a Phase 1 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Nerissa T. Viola.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to investigate the use of \[89Zr\]Zr-DFO-emapalumab as an IFN-γ PET imaging agent to detect lesions and response to therapy among treatment-naïve non-small cell lung cancer (NSCLC) patients. PET scans following the imaging agent will be completed prior to and about 30 days after starting immunotherapy.
Primary Outcome
Descriptively summarize at baseline and post-immunotherapy treatments.
Conditions Studied
Interventions
- DRUG [89Zr]Zr-DFO-emapalumab
Study Locations (1)
Michigan
- Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2029-06 |
| Phase | Phase 1 |
What NCT06439914 shows while recruiting
NCT06439914 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which [89Zr]Zr-DFO-emapalumab is the first listed.
NCT06439914 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT06439914 about?
NCT06439914 is a clinical study titled "First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy". The goal of this clinical trial is to investigate the use of \[89Zr\]Zr-DFO-emapalumab as an IFN-γ PET imaging agent to detect lesions and response to therapy among treatment-naïve non-small cell lung cancer (NSCLC) patients. PET scans following the imaging agent will be completed prior to and about...
What is the current status of trial NCT06439914?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2026-03-09. Estimated completion is 2029-06.
What conditions does trial NCT06439914 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06439914?
The interventions under investigation include: [89Zr]Zr-DFO-emapalumab (DRUG).
Who is sponsoring clinical trial NCT06439914?
This trial is sponsored by Nerissa T. Viola, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06439914 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06439914's enrollment target sits among peer trials
6 449th of 454 higher than 3 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI